Recent high throughput genomic sequencing studies of solid tumors, including head and neck squamous cell carcinoma (SCC), ovarian cancer, lung adenocarcinoma, glioblastoma, breast cancer and lung SCC, have highlighted DNA mutation as a mechanism for aberrant Notch signaling. A primary challenge of targeting Notch for treatment of solid malignancies is determining whether Notch signaling is cancer-promoting or tumor-suppressing for a specific cancer. We compiled reported Notch receptor and ligand missense and nonsense mutations in order glean insights into aberrant Notch signaling.
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Background
The tumor microenvironment for solid malignancies involves a complex interplay of tumor cells, stromal matrix and support cells, blood vessel endothelial cells and immune cells. In order for solid tumors to progress and grow, an adequate blood supply is needed. The interplay between tumor cells and the endothelial cells of blood vessels will be vital to ensure the tumor is adequately supplied with nutrients. The stromal cells and matrix, originally thought to provide a relatively inert support for the process of tumorigenesis and tumor progression, have more recently been appreciated to be co-opted, active participants in these pathological processes. Notch signaling occurs at the interface of these microenvironment compartments ( Figure 1 ).
There are four Notch family receptors in humans, Notch1-4. Each of the four Notch receptors is initially produced as a single polypeptide that is cleaved by a furin-like convertase at site 1 (S1) while in Author Manuscript Published OnlineFirst on July 6, 2012; DOI: 10.1158/1078-0432.CCR- immortalized rat kidney cells in vitro (6) . The DLL4 Notch ligand is highly expressed at the tips and stalks of sprouting vessel endothelial cells and is an important regulator of angiogenesis (7).
The Notch signaling pathway has long been appreciated as functioning in developmental processes and regulating the self-renewal of tissues. More recently, the role of Notch signaling in cancers has been reported with Notch signaling having both oncogenic and tumor suppressive roles, depending on the cellular context. Activating mutations in NOTCH1 were indentified in T cell acute lymphoblastic leukemia and chronic lymphoblastic leukemia (8) (9) (10) , implicating NOTCH1 as an oncogene for these hematopoietic cancers. In the absence of reported NOTCH mutations in solid malignancies prior to 2011, there was already an appreciation that the contribution of Notch signaling to tumor development was largely context dependent, with Notch contributing to tumor development in some instances while suppressing tumorigenesis in other contexts. There have been a number of excellent recent reviews discussing these nuances of Notch signaling (11) (12) (13) (14) . Our goal for this article is to highlight available NOTCH mutation and published functional/correlative data for solid malignancies in order to begin to more fully appreciate the different roles of Notch signaling in cancer and opportunities for therapeutic targeting.
NOTCH receptor mutations in solid malignancies
A number of groups have investigated Notch receptor and ligand mutation status in various tumor types either through whole exome sequence analysis (head and neck squamous cell carcinoma (HNSCC) (15) (16) , ovarian carcinoma (17), colorectal and breast cancers (18) ) or by sequence analysis of entire candidate gene exons including Notch receptors and ligands (breast cancer (19) , glioblastoma (20) , lung adenocarcinoma (21) , and lung squamous cell carcinoma (lung SCC) (22)). Review of these data for nonsilent protein-coding mutations indicated that NOTCH ligands were rarely mutated: JAG1 was mutated in 1 of 91 sequenced glioblastomas and JAG2 was mutated in 2 of 188 lung adenocarcinomas Despite the prevalence of NOTCH1 mutations in HNSCC, the published data are sparse and conflicting regarding the function of Notch1 in these tumors. Notch1 protein levels have been found to be increased in HNSCC compared to adjacent mucosal tissues (23) , and HNSCC tumors expressing higher levels of Notch1 protein were associated with reduced patient survival (24) . However, in separate studies the expression of an activated form of Notch1, the NICD, was reported to result in enhanced or greatly diminished HNSCC cell line in vivo tumorigenicity (24) (25) . The increased frequency of NOTCH1 mutations in lung SCC compared to lung adenocarcinoma and the close proximity of two of the three lung SCC mutations to the ligand-binding domain invites speculation that Notch1 is more likely to function as a tumor suppressor in lung SCC than adenocarcinoma. These lung SCC mutations had a distribution that was similar to cutaneous SCC mutations identified in the same published study, a subset of which were characterized to be loss of function mutations by a cell-based transcription reporter assay (22) . Possible differences in Notch1 function in lung adenocarcinoma versus lung SCC are highlighted by a single report that high tumor Notch1 protein levels were associated with significantly reduced survival for lung adenocarcinoma patients (P=0.004, n=111) but not for lung SCC patients (P=0.23, n=188) (26) . However, reported functions of Notch1 in lung adenocarcinoma are conflicting (27) (28) .
Though NOTCH1 mutations in breast cancer include a missense mutation within the ligandbinding domain and a spectrum that does not differ appreciably from those observed in HNSCC, Notch1 studies in breast cancers have generally reported functional or tumor molecular data implicating Notch1 as an oncogene in these cancers (29) (30) . NOTCH1 mutations occurring in glioblastoma were infrequent and did not map to known functional domains. The functional/correlative data for Notch1 in glioma from two independent reports consistently implicate NOTCH1 as an oncogene (31) (32) . One of the observed NOTCH1 mutations in ovarian carcinoma, P2417A, has also been observed in acute Tlymphoblastic leukemia and maps within PEST domain (33) .
The Notch3 ligand-binding domains are presented in Figure 2 as recently defined by functional studies employing a competitive peptide library screen to include EGF repeats 7-10 and 21-22 (34) .
Mutations observed in HNSCC, ovarian cancer and lung adenocarcinoma occurred in about 1% of these tumors and generally resided within or near recognized functional domains, suggesting these mutations may be loss of function mutations. NOTCH3 sequence data were not yet available for lung SCC.
Research. 
The implications of the spectrum of mutations for NOTCH2 and NOTCH4 receptors were more 
Clinical-Translational Advances
Notch pathway-targeting agents in clinical development for solid malignancies
The appropriate Notch pathway-directed therapeutic is anticipated to differ depending upon whether the tumor harbors a Notch alteration resulting in gain or loss of function. An approach to generally inactivate Notch signaling via inhibition of the γ-Secretase is currently being evaluated as a possible anti-cancer strategy for tumors with acquired Notch gain of function. γ-Secretase has been implicated in Alzheimer's disease as one of the enzyme complexes responsible for cleaving amyloid precursor protein (APP) into amyloid beta, a primary component of amyloid plaques. Because of these pathogenic implications, γ-Secretase inhibitors are in clinical development for several diseases including solid malignancies ( Table 1) .
The finding that a γ-Secretase inhibitor (GSI) resulted in increased incidence of skin cancers with no improvement in Alzheimer's disease symptoms lead to the halt of a large phase III clinical trial (36).
This skin toxicity has been largely attributed to Notch inhibition, and as a result, Notch-sparing GSIs are being developed for treatment of Alzheimer's disease (37-39). The accumulating preclinical and clinical data indicating that Notch is oncogenic in several tumor types has lead to the recent clinical development of GSIs that are not Notch-sparing for treatment of solid tumors.
There are several GSIs that are currently in Phase I or Phase I/II trials for various malignancies (Table 1) . Reports from these early phase trials indicate that the inclusion of biomarkers including tumor levels of Notch proteins, NICD, Notch transcriptional target genes such as HES1 and HEY1 and blood biomarker evaluations were planned for several of these studies (40) (41) (42) . In general, toxicities were manageable. An intermittent dosing schedule appeared to ameliorate gastrointestinal toxicities compared to a continuous dosing regimen (40, 43) . The majority of tumors were positive for Notch1 in trials reporting results (40) (41) . Reported response rates were modest (40) (41) and low baseline levels of IL6 and IL8 were associated with clinical benefit (42) . The finding that the Notch ligand DLL4 is an important regulator of angiogenesis lead to the characterization and development of DLL4-directed therapeutics as a means for interfering with tumor vascularization (Table 1) . No results have been reported for the anti-DLL4 antibody therapeutic, MEDI0639. However the finding that chronic treatment with anti-DLL4 resulted in vascular neoplasms in mice indicates that treatment management will require extra care (44) . Now that Notch1 has been identified as a tumor suppressor, at least in some tissues, administering systemic therapeutics that inhibit general Notch signaling is anticipated to require careful management to reduce additional cancer risks. This would be especially true for patients with early stage disease where the risks of a secondary cancer may outweigh the possible benefits.
Notch-activating agents in clinical development for solid malignancies
Epigenetic silencing of Notch and other tumor suppressor genes is a prominent mechanism for tumor development. Application of agents that interfere with epigenetic silencing of Notch has been reported to reduce tumor-like phenotypes in several preclinical models including neuroendocrine tumors, medullary thyroid cancers and others (45) (46) (47) (48) . Histone deacetylase (HDAC) inhibitors have had some success with NOTCH re-expression in cancers where NOTCH expression was lost by this mechanism. There are two HDAC inhibitors currently in clinical development (Table 1) , and efforts to identify Notch pathway compounds are ongoing (48) . Results from a phase II study of valproic acid (VPA) involving 8 patients with neuroendocrine tumors indicated that Notch1 expression was absent from tumors prior to treatment and increased significantly following VPA treatment. Four of these patients had stable disease as best response (49) .
Tumors harboring more than one predicted NOTCH inactivating mutation are infrequent (15) (16) .
Formal possibilities are that the wildtype allele is present and expressed appropriately in tumors with mutated NOTCH and, therefore, loss of function NOTCH mutations would be described as haploinsufficient. Alternatively, the mutations predicted to be loss of function mutations are in fact gain of function mutations acting through an as yet unknown mechanism. An HDAC inhibitor would not be a rational solution in either case. However, if the wildtype allele is present but transcriptionally repressed, as has been observed for BRCA1 mutations in breast cancers, an HDAC inhibitor may be a viable therapeutic for tumors harboring a NOTCH inactivating mutation. As we learn more about the context and functional consequences of specific NOTCH mutations, we will be better poised to identify appropriate therapeutics for the increasing number of solid tumors with identified NOTCH mutations. 
